Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

GlaxoSmithKline PLC (ADR) (GSK) To Accelerate Filing For COPD Combo Treatment

GlaxoSmithKline plc (ADR) (NYSE:GSK) has come up with a plan that will enable it to file for approval of its triple-combo drug for COPD patients sooner than earlier anticipated. The company reached the decision to accelerate filing of its new drug application (NDA) for its ICS/LAMA/LABA combo after it met with FDA officials.

In the new plan, GlaxoSmithKline will file the NDA for the drug combination by the end of 2016. The company previously planned to seek regulatory clearance of the multiple drug combo treatment in 2018.

Fisher Asset Management is currently the hedge fund with the largest position in GSK at 11.66 million shares, or just below $500 million.

Follow Glaxosmithkline Plc (NYSE:GSK)
Trade (NYSE:GSK) Now!

Beating competition

The accelerated NDA filing for ICS/LAMA/LABA should help GSK unlock a new revenue stream at a time when competitive threat is growing against its drugs in the respiratory treatment market. Several generics manufacturers are preparing to enter the market with copycats of GSK’s drugs, posing serious top-line risks.


Despite the already difficult pricing environment, many generics companies believe there is still room to push prices of branded medicines even lower. Therefore, if GSK secures approval for its COPD triple combo drug next year, it would have an opportunity to protect its revenues from competitive threat in the COPD market.

Branded medications

However, outside of generics, GlaxoSmithKline plc (ADR) (NYSE:GSK) is also keeping an eye on the efforts of rival branded drug developers. These include Novartis AG (NYSE:NVS), AstraZeneca PLC (NYSE:AZN) and Boehringer Ingelheim, which are also active in the branded and combo treatment markets for respiratory and cancer drugs. Nevertheless, the triple combo territory appears to be an area that not many branded drug developers are planning to go into and that might provide GSK some relief.

Multi-combo land

GlaxoSmithKline plc (ADR) (NYSE:GSK) is wading into the triple combo market at a time when cancer researchers recently disclosed that multiple drug combinations could offer much hope in battling cancer. With that in mind, several drug companies are in the process of testing multi-drug combinations for combating cancer. One of the potential areas of challenge is pricing given the growing outcry over expensive drugs with politicians and regulators taking the cue.

Note: This article is written by Andy Parker and originally published at Market Exclusive.

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.